[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-complications":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,83,108,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100648010","extracellular-vesicle-dynamics-predicting-vascular-complications-and-treatment-response-in-systemic-sclerosis-100648010",false,"NCT07717060","Extracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response in Systemic Sclerosis","Extracellular Vesicle Dynamics Across the Circulatory System as Predictors of Major Vascular Complications and Therapeutic Response in Systemic Sclerosis Patients","EVOLVE-SSc","Inclusion Criteria:\n\nMale and female patients aged 45-75 years Diagnosis of systemic sclerosis according to the 2013 ACR\u002FEULAR classification criteria High risk of pulmonary arterial hypertension based on the DETECT algorithm Stable treatment with vasoactive, vasodilator, and immunosuppressive therapies for at least 3 months prior to blood sampling\n\nExclusion Criteria:\n\nPrevious diagnosis of pulmonary arterial hypertension confirmed by right heart catheterization Interstitial lung involvement affecting more than 10% of the lung parenchyma Left-sided heart failure (NYHA class 3-4) Evidence of chronic thromboembolic pulmonary disease on contrast-enhanced CT scan Major contraindications to right heart catheterization or coronary angiography Inability to provide informed consent",true,"ALL","45 Years","75 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"NA","Systemic sclerosis is a multisystem autoimmune disease characterized by vascular dysfunction, immune dysregulation, and progressive tissue fibrosis. Cardiopulmonary complications and peripheral vascular involvement are the principal causes of disability and mortality.\n\nExtracellular vesicles (EVs) have emerged as key mediators of paracrine intercellular communication. Preclinical studies further suggest that EVs mediate long-range inter-organ communication through the circulation. However, the inability to directly track EV trafficking in vivo in humans has limited the understanding of their contribution to systemic inter-organ communication.\n\nThe investigators propose that systemic sclerosis provides a unique human model for investigating circulating EV-mediated inter-organ communication in a multisystem disease. The central hypothesis is that arteriovenous differences in the molecular and cellular characteristics of circulating EVs reflect their dynamic exchange between individual organs and the bloodstream, and that these differences are associated with disease severity. Comparison of EVs across the circulation, rather than relying exclusively on peripheral blood samples, enables a more direct assessment of organ-specific EV release and uptake.\n\nCharacterizing EV dynamics along the circulatory pathway has the potential to identify novel biomarkers and therapeutic targets for systemic sclerosis while providing fundamental insights into EV-mediated inter-organ communication in humans.",[29,30,31,32],"Systemic Sclerosis","Pulmonary Arterial Hypertension","Digital Ulcers","Vascular Complications","NOT_YET_RECRUITING","2026-07-16",{"date":36,"type":37},"2026-07-21","ACTUAL",{"date":39,"type":23},"2026-09-01",{"date":41,"type":23},"2028-09-01",{"name":43,"class":44},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":57,"conditions":58,"keywords":68,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100647502","serpentine-vs-traditional-hydrophilic-guidewire-tracking-in-complex-radial-anatomy-100647502","NCT07707427","Serpentine vs Traditional Hydrophilic Guidewire Tracking in Complex Radial Anatomy","Comparison of the \"Serpentine\" Technique Versus Hydrophilic Guidewire 0,035'' for Navigating Radial and Brachial Artery Loops, Tortuosity and Sharp Angulation During Transradial Access.","S-TRACK","Inclusion Criteria:\n\n* Age ≥18 years\n* Feasibility of TRA\n* Indication for coronary angiography\n* Angiographic documentation of radial or brachial artery loop\u002Ftortuosity\n* Written informed consent\n\nExclusion Criteria:\n\n* STEMI - high risk NSTEMI presentation\n* Hemodynamic instability\n* Anatomical contraindications (e.g., arteriovenous fistula)\n* Significant calcification of the radial or brachial artery on angiographic evaluation.","18 Years",{"count":55,"type":23},204,[26],"Coronary angiography and angioplasty are commonly performed through the radial artery. In some patients, anatomical variations of the radial and brachial arteries, such as loops, increased tortuosity or sharp angulations may pose challenges to equipment advancement.\n\nBoth the hydrophilic guidewire 0,035'' approach and the \"Serpentine\" technique have been described in the literature as techniques for overcoming radial anatomical challenges, with the hydrophilic guidewire approach being the more commonly used method.\n\nIn practical terms, both techniques involve the use of the same standard materials, with differences relating mainly to operator handling and technical manipulation. This study does not introduce any experimental device, material, or treatment; instead, it aims to compare the established approach using a 0.035'' hydrophilic guidewire with the emerging \" Serpentine\" technique with respect to effectiveness, procedural time, and safety.",[59,60,61,62,63,64,65,66,32,67],"Transradial Access(TRA)","Coronary Angiography (CAG)","Percutaneous Coronary Intervention (PCI)","Radial Artery Loop","Radial Artery Tortuosity","Serpentine Technique","Hydrophilic Guidewire","Complex Radial Anatomy","Coronary Catheterization",[69,70,60,61,71,72,64,65,66,32],"Coronary catheterization","Transradial access(TRA)","Radial artery loop","Radial artery tortuosity","RECRUITING","2026-07-15",{"date":34,"type":37},{"date":77,"type":37},"2026-05-14",{"date":79,"type":23},"2029-11",{"name":81,"class":44},"University Hospital of Patras",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":82},"100634150","prospective-exploration-of-vascular-complications-associated-with-the-use-of-immune-checkpoint-inhibitors-100634150","NCT07535944","Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors","Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors in Cancer Treatment: a Multidimensional Study of a Patient Cohort","ICI-Vasc","Inclusion Criteria:\n\n* Patient treated with an ICI (nivolumab, pembrolizumab, atezolizumab, ipilimumab, cemiplima, or any novel antibody directed against PD-1, PD-L1, CTLA-4, or LAG-3) as monotherapy or in combination with another ICI or with radiotherapy,\n* Patient over 18 years of age,\n* WHO performance status: 0 to 2,\n* Oral informed consent,\n* Patient affiliated with or beneficiary of a social security scheme.\n\nExclusion Criteria:\n\n* History of ICI treatment,\n* History of chemotherapy or targeted therapy within the last 4 weeks,\n* Stage 4 PAD,\n* Severe Raynaud's syndrome,\n* Removal of both hands and\u002For both feet,\n* Removal of the right hand\u002Fleft foot or the left hand\u002Fright foot,\n* Patient deprived of liberty by an administrative or judicial decision or patient under legal protection, guardianship, or curatorship,\n* Pregnant or breastfeeding woman,\n* Patient unable to understand the study for any reason or to comply with the trial requirements (language barrier, psychological, geographical, etc.).",{"count":92,"type":23},200,"OBSERVATIONAL","The development of immune checkpoint inhibitors (ICIs) has revolutionized the management of many oncological diseases, and their use continues to increase. ICIs are monoclonal antibodies that target immune checkpoints such as PD-1 (programmed cell death protein 1, as seen in nivolumab, pembrolizumab, and cemiplimab), PD-L1 (programmed cell death protein 1 ligand, as seen in atezolizumab, avelumab, and durvalumab), CTLA-4 (cytotoxic T-lymphocyte antigen 4, as seen in ipilimumab and tremelimumab), or LAG-3 (lymphocyte-activating gene 3, as seen in relatlimab), which play a crucial role in immune tolerance to cancer cells.\n\nHowever, the surge in ICI prescriptions has been accompanied by the occurrence of numerous side effects, some of which are severe or even fatal. ICIs have a different toxicity spectrum than conventional chemotherapy, and most toxicities result from excessive immunity against different organs.\n\nThis immune-mediated toxicity can affect various organ systems, including the heart and blood vessels. Pharmacovigilance data from clinical trials conducted by Bristol-Myers Squibb, which marketed ipilimumab (anti-CTLA-4) and nivolumab (anti-PD1), revealed 18 cases (0.09%) of myocarditis among 20,594 subjects.\n\nWhile cardiac complications induced by immune checkpoint inhibitors (ICIs), particularly autoimmune myocarditis, are widely described, the impact of these treatments on the vascular system remains poorly understood. However, a variety of vascular complications have been reported, ranging from vasculitis of large, medium, and small vessels to a possible increase in arterial thrombotic events, ischemic strokes, and acute coronary syndromes.\n\nThe incidence of vasculitis appears to be between 1% and 2% of patients treated with immune checkpoint inhibitors (ICIs). This is emerging as a significant signal in various pharmacovigilance studies, suggesting the involvement of immune checkpoint derepression in the pathophysiology of vasculitis. A translational study demonstrated the major role of CTLA-4 in the pathophysiology of giant cell arteritis (GCA), although the precise mechanisms involved remain to be determined. Therefore, a specific immune environment could promote the development of vasculitis, a phenomenon reproduced by ICI administration.\n\nThe increase in arterial thrombotic vascular events was primarily observed in a matched cohort study, which showed a threefold increased risk of arterial thrombotic vascular events following the initiation of ICI therapy. These thrombotic events would coincide with the acceleration of atherosclerosis in patients treated with ICIs. This \"accelerated\" atherosclerosis could be linked to inflammatory changes within the plaques, causing plaque destabilization or rupture. It is also unreasonable to rule out the possibility that the accelerated atherosclerosis is related to the development of vasculitis in these patients.",[32],[97,98],"immune checkpoint inhibitors","cancer therapy","2026-06-08",{"date":101,"type":37},"2026-06-10",{"date":103,"type":23},"2026-06-01",{"date":105,"type":23},"2031-06-01",{"name":107,"class":44},"University Hospital, Rouen",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":24,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":82},"100630528","management-of-vascular-complications-in-pediatric-supracondylar-humerus-fractures-100630528","NCT07488845","Management of Vascular Complications in Pediatric Supracondylar Humerus Fractures","Inclusion Criteria:\n\n* ● Children Diagnosed with supracondylar humerus fracture (Gartland I-IV) aged under 15 years.\n\n  * Presented within 1st 48 hrs of injury.\n\nExclusion Criteria:\n\n* ● Old trauma \\>48 hours\n\n  * Previous vascular intervention in the same limb\n  * Another fracture in the same limb","15 Years",{"count":116,"type":23},50,[26],"* To determine the incidence and types of vascular injuries associated with pediatric supracondylar humerus fractures.\n* Identify outcomes of different management strategies\n* Identify risk factors for vascular injury",[32,120],"Supracondylar Humerus Fracture","2026-03-19",{"date":123,"type":37},"2026-03-23",{"date":125,"type":23},"2026-04-01",{"date":127,"type":23},"2027-05-01",{"name":129,"class":44},"Assiut University",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":24,"phases":139,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":82},"100382293","qualitative-and-quantitative-evaluation-of-vascular-flows-of-radial-ulnar-and-interdigital-arterial-trees-under-normal-and-pathological-conditions-by-3-tesla-mri-100382293","NCT04257747","Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI","FLOWHAND","Inclusion Criteria:\n\n* Adult (≥ 18 years old)\n* patients who has received appropriate information and provided informed consent\n* patients benefiting from social security insurance\n* patients with no contraindications to magnetic resonance imaging\n* healthy volunteer or patient requiring radial forearm flap reconstruction or having received hand allotransplantation.\n\nExclusion Criteria:\n\n* Person with a contraindication to MRI\n* pregnant or breastfeeding woman\n* minors (\\\u003C 18 years)\n* person under guardianship or deprived of liberty by a judicial or administrative decision\n* person with upper limb arteriopathy with the exception of the hand transplant patients group.",{"count":138,"type":23},46,[26],"Allotransplants of vascularized composite tissues are subject to chronic vascular rejection, which can lead to graft loss. Currently, no imaging technique allows a reproducible quantitative exploration of the arterial trees of the hand, and therefore a satisfactory monitoring of transplants. Since 2014, flow MRI has been applied to the analysis of small-calibre arteries by the Image Processing Team at the Amiens-Picardie University Hospital. Between 2015 and 2017, several acquisitions were made in 3 patients who received facial allotransplantation, and the team recently developed a flow MRI protocol dedicated to the study of arterial trees in the hand.\n\nThe main objective is to measure vascular flows of radial, ulnar and interdigital arterial trees in normal (healthy volunteers) and pathological situations (patients with radial forearm flap reconstruction and patients with hand allotransplantation) using the specifically developed flow MRI protocol.",[142,32,143,144],"Magnetic Resonance Imaging","Transplantation","Radial Artery",[146,147,148,149,150,151,152],"vascularized composite allotransplantation","hand allotransplantation","radial forearm flap","magnetic resonance imaging","flow MRI","radial artery","ulnar artery","2025-06-05",{"date":155,"type":37},"2025-06-10",{"date":157,"type":37},"2021-09-01",{"date":159,"type":23},"2029-03",{"name":161,"class":44},"Centre Hospitalier Universitaire, Amiens"]